Novel drug selectively kills prostate cancer cells

	Tweet

A team of U.S. scientists has developed an experimental drug treatment that kills prostate cancer cells in mice while sparing normal cells.

The approach is based on delivering small interfering RNAs (siRNAs) to tumor cells, North Carolina-based researchers report in the journal Nature Biotechnology.

In tests in mice with prostate cancer, the researchers found that tumors treated with the experimental RNA-based drug had a 2.21-fold reduction in volume. In contrast, various control tumors left untreated increased in volume by 3.63-fold over a period of about 2 weeks.

The mice given the RNA-based drug showed no ill effects.

“Our initial animal studies using prostate cancer as a model are encouraging,” said study investigator Dr. Bruce A. Sullenger from Duke University Medical Center in Durham, “and we plan to explore the use of this strategy for targeting a variety of other cancers and diseases.”

Moreover, he and his colleagues intend to “evaluate the potential of this approach in ... clinical studies in the next few years.”

Explaining the rationale behind the RNA-based strategy, Sullenger told Reuters Health: “RNA is such a multifaceted molecule, that a single molecule of RNA can simultaneously trick cells into taking it up via a targeting RNA sequence and shut down the expression of an essential cancer survival gene via a silencing RNA sequence.”

The approach is a “simple yet elegant” way to target cancer cells for destruction without harming normal cells, he said.

SOURCE: Nature Biotechnology August 2006.

RELATED STORIES:
Noninvasive prostate treatment developed   Sometimes No Treatment is the Right Option for Low-Risk Prostate Cancer   New Treatment for Advanced Prostate Cancer   Botox relieves BPH symptoms   Genetic factors key to prostate cancer death risk   Profiling prostate cancer   Most prostate cancer patients opt for surgery   Obesity linked to higher risk of prostate cancer progression   Prostate Cancer Translational Research in Europe meeting: Search for biomarkers continues   On Sex After Prostate Surgery, Confusing Data   Stem Cells Found in Prostate May Be Involved in Cancer   New Bcl-2 Inhibitor Shows Promise in Cell Death in Prostate Cancer   Many men struggle to work after prostate cancer   Rotating-shift work tied to prostate cancer risk   Chlordecone exposure and risk of prostate cancer   Scientists Target Aggressive Prostate Cancer   Overweight men risk prostate cancer recurrence   Dramatic Outcomes in Prostate Cancer Study   Prediction models help determine likelihood of erectile function after treatment for prostate cancer   Scientists discover way to block growth of prostate cancer cells   Surgeon’s skill affects prostate cancer relapse   No Evidence That Widely Prescribed Statins Protect Against Prostate Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]